PP  Vol.5 No.7 , June 2014
Application of D-Optimal Study Design with Contour Surface Response for Designing Sustained Release Gliclazide Matrix Tablets
Abstract: An optimized formulation of a sustained release tablet of Gliclazide was developed. The use of Doptimal design with a polynomial statistical model to analyze dissolution data reduced the number of laboratory tests required to obtain an optimal dosage form. The final formulation contained 22 mg of Methocel®E15LV, 16.5 mg Methocel®E15 and 10.0 mg of Dibasic Calcium Phosphate per 30 mg Gliclazide sustained release tablet. Dissolution studies performed on tablets from 5000 tablet test batches released greater than 90 percent of loaded drug in eight hours. Drug release from the optimized tablets followed a pattern more closely similar to zero-order than other mechanisms of drug release tested. Storage of tablets in accelerated and ambient conditions for 6 and 12 months respectively did not alter any of the physico-chemical properties, drug release or the drug release rate compared to initial observations and dissolution data of the prepared tablets. The addition of potassium phosphate and monosodium phosphate to the tablet reduced the effect pH has on Gliclazide dissolution compared to the commercially available product.
Cite this paper: Nguyen, C. , Christensen, J. and Nguyen, T. (2014) Application of D-Optimal Study Design with Contour Surface Response for Designing Sustained Release Gliclazide Matrix Tablets. Pharmacology & Pharmacy, 5, 620-635. doi: 10.4236/pp.2014.57072.

[1]   Naji, N., Nasir, I., Beshtawi, M., Mohammed, B., Admour, I., Mahmood, S.A., Zaman, Q. and Dham, R. (2002) Bioequivalence Evaluation of Two Brands of Gliclazide 80 mg Tablets (Gliclazide and Diamicron) in Healthy Human Volunteers. Biopharmaceutics and Drug Disposition, 23, 197-202.

[2]   Hong, S.S., Lee, S.H., Lee, Y.J., Chung, S.J., Lee, M.H. and Shim, C.K. (1998) Accelerated Oral Absorption of Gliclazide in Human Subjects from a Soft Gelatin Capsule Containing a PEG 400 Suspension of Gliclazide. Journal of Controlled Release, 51, 185-192.

[3]   Delrat, P., Paraire, M. and Jochemsen, R. (2002) Complete Bioavailability and Lack of Food-Effect on Pharmacokinetics of Gliclazid 30 mg Modified Release in Healthy Volunteers. Biopharmaceutics & Drug Disposition, 23, 151-157.

[4]   Barochez, B.H.D., Wuthrich, P. and Martin, L. (2004) Core Tablet for Controlled Release of Gliclazide after Oral Administration. US Patent No: 6733782.

[5]   Murpani, D. and Madan, A. (2006) Modified Release Formulation of Gliclazide. US Patent Application WO 2006/ 123213 A1.

[6]   Wit, J.B. and Doshi, H.A. (2006) Sustained-Release Formulation of Gliclazide. European Patent Application 2181705.

[7]   Jin, X., Zhang, Y., Xaio, L. and Zhao, Z. (2008) Optimization of Extended Zero-Order Release Gliclazide Tablets Using D-Optimal Mixture Design. Yakugaku Zasshi, 128, 1475-1483.

[8]   Raja Rajeswari, K., Abbulu, K., Sudhakar, M. and Ravi, N. (2011) Formulation and in Vitro Evaluation of Hydrogel Matrices of Gliclazide Modified Release Tablets. International Journal of Pharmacy, 1, 82-87.

[9]   Srivastav, M., Prabharkar, B. and Omray, A. (2011) Effect of Alkaline Excipients on the Release Profile of Gliclazide Extended Release Tablets. Journal of Pharmaceutical Science and Technology, 3, 462-470.

[10]   Vijayalakshmi, P., Devi, V.K., Narendra, C. and Srinagesh, S. (2008) Development of Extended Zero-Order Release Gliclazide Tablets by Central Composite Design. Drug Development and Industrial Pharmacy, 34, 33-45.

[11]   Jeyaprabha, P., Sudhamani, T., Mahendra, H., Ganesan, V. and Senthil, S.P. (2010) Formulation and Evaluation of Gliclazide Modified Release Tablets Using Hydroxypropyl Cellulose. International Research Journal of Pharmacy, 1, 282-287.

[12]   Li, W., Du, G., Yang, Z., Zhang, Z., Nie, S., Peng, B. and Pan, W. (2008) In Vitro and in Vivo Evaluation of a Novel Push-Pull Osmotic Pump with Orifices on Both Surfaces. Drug Development and Industrial Pharmacy, 34, 1350-1355.

[13]   Kumar, M.S., Ramakrishna, R. and Kumar, N.N. (2010) Design and Development of Oral Controlled Release Formulations of Gliclazide Using Natural Polymers. International Research Journal of Pharmacy, 1, 233-242.

[14]   Devarajan, P.V. and Sonavane, G.S. (2007) Preparation and in Intro/in Vivo Evaluation of Gliclazide Loaded Eudragit Nanoparticles as a Sustained Release Carrier. Drug Development and Industrial Pharmacy, 33, 101-111.

[15]   Varshosaz, J., Tavakoli, N., Minayian, M. and Rahdari, N. (2009) Applying the Taguchi Design for Optimized Formulation of Sustained Release Gliclazide Chitosan Beads an in Vitro/in Vivo Study. AAPS PharmSciTech, 10, 158-164.

[16]   Barakat, N.S. and Almurshedi, A.S. (2010) Design and Development of Gliclazide-Loaded Chitosan Microparticles for Oral Sustained Drug Delivery: In Vitro/in Vivo Evaluation. Journal of Pharmacy and Pharmacology, 62, 169-178.

[17]   Wang, L., Wang, J., Lin, X. and Tang, X. (2010) Preparation and in Vitro Evaluation of Gliclazide Sustained-Release Matrix Pellets: Formulation and Storage Stability. Drug Development and Industrial Pharmacy, 36, 814-822.

[18]   Hussain, T., Saeed, T., Mumtaz, A.M., Javid, Z., Abbas, K., Awais, A. and Idrees, H.A. (2013) Effect of Two Hydrophobic Polymers on the Release of Gliclazide from Their Matrix Tablets. ACTA Poloniae Pharmaceutica-Drug Research, 70, 749-757.

[19]   Kumar, C.S., Reddy-Budidti, K.K., Battula, S.P. and Ayyavala, C.S. (2013) Formulation and Evaluation of Ficusglomerata Mucilage Sustained Release Matrix Tablets. Pakistan Journal of Pharmaceutical Sciences, 24, 399-404.

[20]   Costa, P. and Manuel, J. (2001) Modeling and Comparison of Dissolution Profiles. European Journal of Pharmaceutical Science, 13, 123-133.

[21]   Badgujar, P. and Shaikh, T. (2013) Development of Dissolution Media for Marketed Gliclazide Modified Release Tablets. Pharma Sience Monitor, 4, 35-363.